Stoke Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Stoke Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||
| cash and cash equivalents | 101,472,000 | 274,817,000 | 127,983,000 | 150,016,000 | 193,476,000 | 178,581,000 | 191,442,000 | 189,977,000 | 192,060,000 | 190,339,000 | 113,556,000 | 113,396,000 | 67,754,000 | 84,111,000 | 144,895,000 | 149,038,000 | 169,070,000 | 267,514,000 | 287,308,000 | 191,461,000 | 201,930,000 | 211,288,000 | 222,471,000 | 233,049,000 | 242,680,000 |
| marketable securities - current | 146,236,000 | 82,507,000 | 89,184,000 | ||||||||||||||||||||||
| prepaid expenses | 13,694,000 | 12,694,000 | 11,117,000 | 9,837,000 | 10,345,000 | 10,722,000 | 11,320,000 | 10,936,000 | 10,950,000 | 10,191,000 | 10,932,000 | ||||||||||||||
| restricted cash - current | 75,000 | 75,000 | 75,000 | ||||||||||||||||||||||
| interest receivable | 1,622,000 | 606,000 | 700,000 | 691,000 | 305,000 | 11,000 | 64,000 | 96,000 | 136,000 | 492,000 | 588,000 | 395,000 | 350,000 | 265,000 | 132,000 | 45,000 | 131,000 | 6,000 | 6,000 | 2,000 | 9,000 | 144,000 | 281,000 | 376,000 | 260,000 |
| other current assets | 6,871,000 | 5,037,000 | 3,965,000 | 3,809,000 | 4,287,000 | 3,559,000 | 2,561,000 | 4,269,000 | 3,699,000 | 5,880,000 | 2,955,000 | ||||||||||||||
| total current assets | 269,970,000 | 375,736,000 | 232,756,000 | 253,612,000 | 296,994,000 | 193,275,000 | 215,339,000 | 230,019,000 | 246,232,000 | 270,236,000 | 244,070,000 | 264,601,000 | 289,159,000 | 305,771,000 | 229,218,000 | 244,933,000 | 260,233,000 | 275,295,000 | 293,930,000 | 195,456,000 | 205,544,000 | 215,774,000 | 226,033,000 | 236,680,000 | 244,445,000 |
| marketable securities - long-term | 107,256,000 | 22,989,000 | 29,952,000 | ||||||||||||||||||||||
| restricted cash - long-term | 721,000 | 721,000 | 494,000 | 494,000 | |||||||||||||||||||||
| operating lease right-of-use assets | 3,218,000 | 3,831,000 | 4,345,000 | 4,928,000 | 5,499,000 | 6,060,000 | 6,611,000 | 3,084,000 | 3,646,000 | 4,202,000 | 4,753,000 | 5,295,000 | 5,831,000 | 4,563,000 | 4,939,000 | 5,326,000 | 1,258,000 | 844,000 | 1,115,000 | 1,381,000 | 1,642,000 | 1,900,000 | |||
| property and equipment | 3,343,000 | 3,611,000 | 3,909,000 | 4,333,000 | 4,770,000 | 5,278,000 | 5,823,000 | 6,217,000 | 6,472,000 | 6,789,000 | 6,675,000 | 7,161,000 | 5,868,000 | 5,035,000 | 4,139,000 | 2,943,000 | 2,884,000 | 2,711,000 | 2,675,000 | 2,893,000 | 2,823,000 | 2,962,000 | 2,512,000 | 1,942,000 | 1,722,000 |
| total assets | 384,508,000 | 406,888,000 | 271,555,000 | 293,319,000 | 307,757,000 | 205,182,000 | 228,342,000 | 239,889,000 | 256,919,000 | 281,796,000 | 256,067,000 | 277,626,000 | 301,427,000 | 315,938,000 | 238,865,000 | 253,771,000 | 264,450,000 | 278,908,000 | 297,925,000 | 199,935,000 | 210,214,000 | 220,841,000 | 228,750,000 | 238,827,000 | 246,372,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||
| accounts payable | 4,313,000 | 2,186,000 | 2,498,000 | 2,485,000 | 3,945,000 | 2,102,000 | 1,695,000 | 3,076,000 | 1,556,000 | 4,299,000 | 766,000 | 1,911,000 | 3,602,000 | 3,328,000 | 2,385,000 | 655,000 | 963,000 | 1,496,000 | 1,495,000 | 1,095,000 | 904,000 | 1,779,000 | 751,000 | 1,789,000 | 1,238,000 |
| accrued and other current liabilities | 25,616,000 | 24,335,000 | 18,567,000 | 15,768,000 | 14,500,000 | 12,570,000 | 13,815,000 | 13,390,000 | 12,222,000 | 13,777,000 | 15,748,000 | 14,046,000 | 13,413,000 | 11,108,000 | 14,754,000 | 11,229,000 | 7,234,000 | 4,614,000 | 9,930,000 | 5,640,000 | 4,901,000 | 3,676,000 | 3,350,000 | 3,127,000 | 3,580,000 |
| deferred revenue - current portion | 8,749,000 | 18,164,000 | 18,991,000 | 31,612,000 | 26,051,000 | 20,918,000 | 15,309,000 | 8,735,000 | 8,059,000 | 13,451,000 | 14,880,000 | 12,838,000 | 10,634,000 | 8,469,000 | |||||||||||
| total current liabilities | 38,678,000 | 44,685,000 | 40,056,000 | 49,865,000 | 44,496,000 | 35,590,000 | 30,819,000 | 25,201,000 | 21,837,000 | 31,527,000 | 31,394,000 | 28,795,000 | 27,649,000 | 22,905,000 | 17,139,000 | 11,884,000 | 8,197,000 | 6,110,000 | 11,425,000 | 6,735,000 | 5,805,000 | 5,455,000 | 4,101,000 | 4,916,000 | 4,818,000 |
| deferred revenue - net of current portion | 9,632,000 | 10,255,000 | 8,291,000 | 16,946,000 | 25,042,000 | 33,074,000 | 40,730,000 | 43,258,000 | 34,144,000 | 36,856,000 | 41,078,000 | 45,210,000 | 49,545,000 | ||||||||||||
| other long term liabilities | 1,255,000 | 1,874,000 | 2,478,000 | 3,050,000 | 3,606,000 | 4,208,000 | 4,884,000 | 959,000 | 1,629,000 | 2,303,000 | 2,968,000 | 3,610,000 | 4,247,000 | 3,511,000 | |||||||||||
| total long term liabilities | 10,887,000 | 12,129,000 | 2,478,000 | 11,341,000 | 20,552,000 | 29,250,000 | 37,958,000 | 41,689,000 | 44,887,000 | 36,447,000 | 39,824,000 | 44,688,000 | 49,457,000 | 53,056,000 | |||||||||||
| total liabilities | 49,565,000 | 56,814,000 | 42,534,000 | 61,206,000 | 65,048,000 | 64,840,000 | 68,777,000 | 66,890,000 | 66,724,000 | 67,974,000 | 71,218,000 | 73,483,000 | 77,106,000 | 75,961,000 | 21,088,000 | 16,258,000 | 9,381,000 | 6,443,000 | 11,847,000 | 7,400,000 | 6,814,000 | 6,499,000 | 4,322,000 | 5,144,000 | 4,836,000 |
| commitments and contingencies | |||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||
| common stock | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 |
| additional paid-in capital | 736,276,000 | 728,124,000 | 719,997,000 | 712,290,000 | 696,637,000 | 568,560,000 | 561,433,000 | 548,033,000 | 540,919,000 | 534,111,000 | 483,170,000 | 477,337,000 | 470,977,000 | 461,389,000 | 414,024,000 | 409,166,000 | 404,145,000 | 399,532,000 | 396,352,000 | 288,249,000 | 285,430,000 | 283,413,000 | 282,460,000 | 281,555,000 | 280,804,000 |
| accumulated other comprehensive income | 96,000 | 166,000 | |||||||||||||||||||||||
| accumulated deficit | -401,434,000 | -377,951,000 | -490,830,000 | -480,348,000 | -453,918,000 | -428,223,000 | -401,849,000 | -374,891,000 | -350,349,000 | -319,695,000 | -297,150,000 | -271,495,000 | -245,384,000 | -220,732,000 | -196,083,000 | -171,635,000 | -149,038,000 | -127,071,000 | -110,278,000 | -95,717,000 | -82,033,000 | -69,074,000 | -58,035,000 | -47,875,000 | -39,271,000 |
| total stockholders’ equity | 334,943,000 | 350,074,000 | 229,021,000 | 232,113,000 | 242,709,000 | 140,342,000 | 159,565,000 | 172,999,000 | 190,195,000 | 213,822,000 | 184,849,000 | 204,143,000 | 224,321,000 | 239,977,000 | 217,777,000 | 237,513,000 | 255,069,000 | 272,465,000 | 286,078,000 | 192,535,000 | 203,400,000 | 214,342,000 | 224,428,000 | 233,683,000 | 241,536,000 |
| total liabilities and stockholders’ equity | 384,508,000 | 406,888,000 | 271,555,000 | 293,319,000 | 307,757,000 | 205,182,000 | 228,342,000 | 239,889,000 | 256,919,000 | 281,796,000 | 256,067,000 | 277,626,000 | 301,427,000 | 315,938,000 | 238,865,000 | 253,771,000 | 264,450,000 | 278,908,000 | 297,925,000 | 199,935,000 | 210,214,000 | 220,841,000 | 228,750,000 | 238,827,000 | 246,372,000 |
| accumulated other comprehensive loss | -104,000 | -151,000 | -15,000 | -24,000 | -147,000 | -379,000 | -598,000 | -1,175,000 | -1,703,000 | -1,276,000 | -684,000 | -168,000 | -22,000 | -42,000 | |||||||||||
| marketable securities - short term | 88,916,000 | ||||||||||||||||||||||||
| restricted cash - short term | 75,000 | ||||||||||||||||||||||||
| restricted cash - long term | 721,000 | ||||||||||||||||||||||||
| marketable securities - long term | 29,824,000 | ||||||||||||||||||||||||
| marketable securities | 88,506,000 | 9,952,000 | 24,741,000 | 39,387,000 | 63,334,000 | 116,039,000 | 138,259,000 | 207,876,000 | 209,105,000 | 74,915,000 | 87,118,000 | 82,156,000 | |||||||||||||
| restricted cash - short-term | 75,000 | 147,000 | 147,000 | 147,000 | |||||||||||||||||||||
| deferred financing costs | 402,000 | 117,000 | 117,000 | 117,000 | 117,000 | 181,000 | 378,000 | 77,000 | |||||||||||||||||
| restricted cash | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 569,000 | 75,000 | 58,000 | 205,000 | 205,000 | 205,000 | 205,000 | 205,000 | 205,000 | 205,000 | |||||
| prepaid expenses and other current assets | 12,551,000 | 13,179,000 | 12,290,000 | 9,159,000 | 8,468,000 | 8,612,000 | 7,511,000 | 6,435,000 | 3,615,000 | 3,528,000 | 4,342,000 | 3,281,000 | 3,255,000 | 1,505,000 | |||||||||||
| long term liabilities | 3,949,000 | 4,374,000 | 1,184,000 | 333,000 | 422,000 | 665,000 | 1,009,000 | 1,044,000 | 221,000 | 228,000 | 18,000 | ||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized, none issued and outstanding as of december 31, 2019; and no shares authorized, issued or outstanding as of december 31, 2018 | |||||||||||||||||||||||||
| convertible preferred stock, par value of 0.0001 per share; no shares authorized, issued or outstanding at december 31, 2019; 225,584,874 shares authorized, 22,677,585 shares issued and outstanding as of december 31, 2018, aggregate liquidation preference of 130,850 at december 31, 2018 | |||||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized, none issued and outstanding as of september 30, 2019; and no shares authorized, issued or outstanding as of december 31, 2018 | |||||||||||||||||||||||||
| convertible preferred stock, par value of 0.0001 per share; no shares authorized, issued or outstanding at september 30, 2019; 22,677,585 shares issued and outstanding as of december 31, 2018; aggregate liquidation preference of 130,850 at december 31, 2018 | |||||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized, none issued and outstanding as of june 30, 2019; and none authorized as of december 31, 2018 | |||||||||||||||||||||||||
| convertible preferred stock, par value of 0.0001 per share; no shares authorized, issued or outstanding at june 30, 2019; 22,677,585 shares issued and outstanding as of december 31, 2018; aggregate liquidation preference of 130,850 at december 31, 2018 |
We provide you with 20 years of balance sheets for Stoke Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Stoke Therapeutics. Explore the full financial landscape of Stoke Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Stoke Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.